Removal of Protein-Bound Uremic Toxins by Liposome-Supported Peritoneal Dialysis

Perit Dial Int. 2019 Nov-Dec;39(6):509-518. doi: 10.3747/pdi.2018.00229.

Abstract

Background:Protein-bound uremic toxins (PBUTs) are poorly cleared by peritoneal dialysis (PD). This study aimed to enhance PBUT removal in PD by adding a binder to the peritoneal dialysate and to evaluate the feasibility and efficacy of liposome-supported PD (LSPD) to increase the removal of PBUTs compared with albumin PD.Methods:Removal of p-cresyl sulfate (PCS), indoxyl sulfate (IS), and indole-3-acetic acid (3-IAA) was first evaluated in an in vitro PD model using artificial plasma preloaded with test solutes. Male Sprague-Dawley rats (n = 24) were then subjected to 5/6 nephrectomy and fed for 16 weeks to establish end-stage renal failure, after which they were treated with either conventional glucose-based PD, albumin-based PD, or liposome-based PD. Removal of PBUTs and small water-soluble solutes was determined during a 6-hour PD dwell.Results:In vitro experiments showed that adding albumin as a toxin binder to the dialysate markedly increased the removal of PCS, IS, and 3-IAA compared with the control. The uptake capacity of liposomes was comparable with that of albumin for PCS and 3-IAA, though slightly inferior for IS. In vivo PD in uremic rats demonstrated that LSPD resulted in higher intraperitoneal concentrations and more total mass removal for PBUTs than the conventional glucose-based PD, which was comparable with albumin PD.Conclusions:Supplementing conventional glucose-based PD solutions with a binder could efficiently increase the removal of PBUTs. This preliminary study suggested that LSPD may be a promising alternative to albumin PD for increasing PBUT removal in the development of next-generation PD solutions for PD patients.

Keywords: Bound solute dialysis; albumin; biocompatibility; peritoneal dialysis solution.

MeSH terms

  • Animals
  • Dialysis Solutions / pharmacology*
  • Disease Models, Animal
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / therapy*
  • Liposomes / pharmacology*
  • Male
  • Peritoneal Dialysis / methods*
  • Rats
  • Rats, Sprague-Dawley
  • Serum Albumin / adverse effects*
  • Serum Albumin / metabolism
  • Toxins, Biological / adverse effects*

Substances

  • Dialysis Solutions
  • Liposomes
  • Serum Albumin
  • Toxins, Biological